Drug-Resistant Bacteria Spread Beyond Hospitals
Drug-resistant bacteria are no longer confined to hospital settings but are increasingly spreading into communities across all countries.
Why the Surge in STIs in Europe Matters Globally
Why should a surge in sexually transmitted infections (STIs) in Europe be a concern for Africa or for individuals who do not consider themselves at risk? This trend highlights a larger issue: the ease with which drug-resistant infections are now disseminating, not only within hospitals but also throughout communities.
The rapid pace and extensive scale of human travel and interaction in our interconnected world facilitate this spread, enabling drug-resistant pathogens to move swiftly through populations and across continents. This includes transmission between high-income countries and low- and middle-income countries (LMICs), where the burden of disease is often greatest and surveillance systems are more limited.
Evidence from Drug-Resistant Gonorrhoea
Evidence of this phenomenon is apparent in the unprecedented rise in cases of drug-resistant gonorrhoea infections. Globally, there were an estimated 82 million new gonorrhoea infections in 2020—the majority occurring in LMICs. Increasingly, these infections are becoming more difficult, and in some cases nearly impossible, to treat due to resistance to antibiotics that previously controlled them.
Health systems in many LMICs are already under significant strain, which exacerbates the consequences of untreatable infections. This resurgence should not be viewed as an anomaly but rather as an early warning sign of how other drug-resistant infections are spreading in our environment.
Drug Resistance Beyond Hospitals
Drug resistance is often perceived as a problem limited to hospital environments, threatening patients in intensive care units or cancer wards. However, the bacteria responsible for these infections do not remain confined to clinical settings, nor do they necessarily originate there. They move with and among people—across cities, borders, and continents—carried not only by those who are infected but also by individuals who are unknowingly colonized.
While STIs require sexual contact for transmission, drug-resistant bacteria can spread through more routine interactions or persist on surfaces and objects long enough to travel with people. In a world where billions of journeys occur annually, migration, travel, and trade are constants, and where increasing numbers of people reside in dense urban areas—especially in rapidly growing cities in LMICs—this is a significant concern. It means antimicrobial resistance (AMR) can circulate globally and spread among populations with remarkable ease.
Global Spread of Extensively Drug-Resistant Gonorrhoea
This dynamic is now evident in the transmission of extensively drug-resistant strains of Neisseria gonorrhoeae through sexual contact, with such strains first detected in Cambodia and subsequently identified as far afield as France and Australia. This development is particularly alarming because N. gonorrhoeae has developed resistance to multiple antibiotics used for treatment, leaving only one last recommended antibiotic, ceftriaxone, available. With an increasing number of cases resistant even to ceftriaxone, gonorrhoea risks becoming one of the first diseases that can no longer be effectively treated.
While similar resistance is emerging in other bacteria, detection often occurs only after these infections reach hospital settings. Nevertheless, these drug-resistant bacteria are present and spreading in the community. The gene mcr-1, which confers resistance to colistin—a last-resort antibiotic—was first identified in the 1990s and rapidly disseminated across countries, becoming established worldwide within just over a decade.
Community-Acquired Drug-Resistant Infections
Drug-resistant infections can become entrenched in hospitals, but evidence now indicates that infections such as methicillin-resistant Staphylococcus aureus (MRSA) acquired in everyday environments are also becoming more prevalent and dangerous, especially for vulnerable groups like cancer patients. In LMICs, where outpatient care is more common and infection prevention resources are limited, these risks are amplified.
Large-scale studies report high rates of drug-resistant infections among cancer patients receiving outpatient care, with infections such as pneumonia occurring more frequently and carrying a significant risk of mortality.
Implications for Response Strategies
Collectively, these trends signal a broader shift in the threat posed by drug-resistant infections, with important implications for response strategies. Improved antibiotic stewardship, which reduces overuse and inappropriate use of antibiotics, is essential as these are key drivers of AMR. Although many governments are attempting to implement such measures, stewardship and infection control alone are insufficient to address the problem.
For an increasing number of infections—particularly those that are most difficult to treat and deadly—resistance is outpacing antibiotic development. Antibiotics are being lost faster than they are being replaced, with many bacterial infections now resistant to first-line treatments.
This represents a significant blind spot in the global AMR response. The traditional commercial model for research and development focuses on producing the most profitable antibiotics, repeatedly failing to deliver those most urgently needed—especially for populations in LMICs, where the need is greatest but expected financial returns are lowest.
Innovative Models for Antibiotic Development
A new model is required to ensure the development of appropriate antibiotics, and recent progress demonstrates how this can be achieved. The first-in-class antibiotic for multidrug-resistant gonorrhoea, developed through a not-for-profit model led by the Global Antibiotic Research & Development Partnership (GARDP) and partners, is the first new treatment for this disease in decades. This approach prioritizes global public health needs, access, stewardship, and sustainable use across all countries rather than profit margins.
The Urgency of the AMR Crisis
In the coming years, these new antibiotics will be essential as AMR has reached a tipping point. Nearly 5 million deaths annually are related to AMR, and this number is expected to rise.
What makes this moment particularly dangerous is not only the scale of the problem but also the changing nature of the threat. As drug-resistant infections establish themselves in the community, the boundary between everyday life and high-risk settings is disappearing. Ordinary interactions—at home, work, and in public—are becoming pathways for infections that are increasingly difficult to treat.
Unless decisive action is taken, we risk a future where common infections can no longer be reliably treated, with consequences extending far beyond hospital walls.
